Strides Pharma Science Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

Technical Trend Overview and Price Movement

As of 16 Feb 2026, Strides Pharma Science Ltd (NSE: 688428) closed at ₹859.80, down 0.67% from the previous close of ₹865.60. The stock traded within a range of ₹848.25 to ₹870.75 during the session, remaining well below its 52-week high of ₹1,024.90 but comfortably above the 52-week low of ₹551.00. This price action reflects a consolidation phase after a period of strong gains.

The technical trend has shifted from mildly bullish to sideways, signalling a pause in upward momentum. This is corroborated by the weekly and monthly MACD readings, both mildly bearish, indicating that the momentum behind recent gains is weakening. The Moving Average Convergence Divergence (MACD) is a key momentum indicator, and its bearish tone on weekly and monthly charts suggests that the stock may face resistance in sustaining upward moves in the near term.

Momentum Oscillators: RSI and KST Analysis

The Relative Strength Index (RSI) presents a mixed picture. On the weekly timeframe, RSI shows no clear signal, hovering in a neutral zone that neither favours buyers nor sellers. However, the monthly RSI is bearish, indicating that the stock’s longer-term momentum is under pressure. This divergence between weekly and monthly RSI readings suggests that while short-term price action may stabilise, the broader trend is losing strength.

The Know Sure Thing (KST) oscillator, which aggregates multiple rate-of-change indicators, also aligns with this cautious outlook. Both weekly and monthly KST readings are mildly bearish, reinforcing the view that momentum is decelerating. This is a warning sign for investors who had previously benefited from the stock’s strong upward trajectory.

Moving Averages and Bollinger Bands: Conflicting Signals

Daily moving averages remain mildly bullish, indicating that short-term price trends still favour the upside. This suggests that despite recent weakness, the stock retains some upward bias in the near term. However, Bollinger Bands present a more complex scenario. On the weekly chart, Bollinger Bands are bearish, signalling increased volatility and potential downward pressure. Conversely, the monthly Bollinger Bands are mildly bullish, hinting at a possible stabilisation or gradual recovery over a longer horizon.

This divergence between short- and long-term volatility measures highlights the stock’s current indecision phase, where investors are weighing recent gains against emerging risks.

Volume and Dow Theory Perspectives

On-Balance Volume (OBV) analysis shows mildly bullish signals on the weekly timeframe, suggesting that volume trends are still supporting price advances in the short term. However, the monthly OBV shows no clear trend, indicating that longer-term volume support is lacking. This mixed volume picture adds to the uncertainty surrounding the stock’s immediate direction.

Dow Theory assessments further complicate the outlook. Weekly Dow Theory readings are mildly bullish, consistent with short-term moving averages, but monthly readings show no discernible trend. This suggests that while short-term technicals may encourage cautious optimism, the broader market context does not yet confirm a sustained uptrend.

Comparative Performance and Market Context

Strides Pharma’s recent price momentum must be viewed in the context of its relative performance against the broader market. Over the past week, the stock declined by 0.47%, outperforming the Sensex’s 1.14% fall. However, over the last month, Strides Pharma’s return of -7.31% significantly underperformed the Sensex’s modest -1.20% decline. Year-to-date, the stock is down 4.72%, lagging the Sensex’s 3.04% loss.

Despite recent underperformance, Strides Pharma has delivered impressive long-term returns. Over one year, the stock has surged 26.22%, outperforming the Sensex’s 8.52% gain. The three-year return is particularly striking at 496.31%, dwarfing the Sensex’s 36.73%. Even over five and ten years, Strides Pharma has outpaced the Sensex, with returns of 101.34% and 85.85% respectively, compared to the Sensex’s 60.30% and 259.46%. This long-term outperformance underscores the company’s strong fundamentals and growth prospects within the Pharmaceuticals & Biotechnology sector.

Mojo Score and Analyst Ratings

MarketsMOJO assigns Strides Pharma a Mojo Score of 56.0, reflecting a Hold rating. This is an upgrade from the previous Sell grade, which was changed on 09 Feb 2026. The Market Cap Grade stands at 3, indicating a mid-tier market capitalisation relative to peers. The upgrade in rating suggests that while the stock is not currently a strong buy, it has improved technical and fundamental attributes warranting cautious optimism.

Investors should note that the Hold rating aligns with the mixed technical signals observed. The mildly bullish daily moving averages and weekly Dow Theory readings offer some support, but the bearish monthly MACD and RSI temper enthusiasm. This balanced view encourages investors to monitor the stock closely for confirmation of trend direction before committing additional capital.

Investor Takeaway and Outlook

Strides Pharma Science Ltd currently sits at a technical crossroads. The shift from a mildly bullish to a sideways trend reflects a market digesting recent gains and awaiting fresh catalysts. The mixed signals from MACD, RSI, Bollinger Bands, and KST oscillators suggest that momentum is fragile, with short-term indicators offering some support but longer-term measures signalling caution.

Investors should consider the stock’s strong historical performance and upgraded Mojo Grade as positive factors, but remain vigilant for confirmation of trend direction. A sustained break above recent highs near ₹870 could reignite bullish momentum, while a drop below the current support zone near ₹848 may signal further consolidation or correction.

Given the Pharmaceuticals & Biotechnology sector’s inherent volatility and sensitivity to regulatory and innovation news, technical analysis should be complemented with fundamental monitoring. Upcoming earnings reports, product launches, or sector developments could provide the necessary impetus to resolve the current technical ambiguity.

Summary

In summary, Strides Pharma Science Ltd’s technical parameters reveal a nuanced momentum shift. While daily moving averages and weekly volume trends offer some bullish undertones, the broader monthly indicators caution against over-optimism. The stock’s recent price action and relative performance against the Sensex highlight both resilience and vulnerability. Investors are advised to adopt a balanced approach, leveraging technical signals alongside fundamental insights to navigate the evolving landscape.

Unlock special upgrade rates for a limited period. Start Saving Now →